Issue: October 2024
Fact checked byErik Swain

Read more

September 09, 2024
1 min read
Save

Tubeless insulin patch pump receives FDA clearance for type 1 and type 2 diabetes

Issue: October 2024
Fact checked byErik Swain
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • The FDA granted 510(k) clearance for a tubeless insulin patch pump system.
  • The system includes a patch pump with 300 U insulin reservoir designed to be used for up to 3 days.

The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced.

The FDA cleared Embecta’s disposable insulin delivery system, which includes a tubeless patch pump with a 300 U insulin reservoir that allows for adjustable basal and bolus insulin for up to 3 days, according to a press release issued by the company. The system also includes a locked-down controller with Bluetooth wireless technology and a color touch screen.

Image: Healio
The FDA has granted 510(k) clearance for a disposable insulin delivery system that includes a tubeless patch pump with a 300 U insulin reservoir.

The system’s design was informed by feedback from people with type 2 diabetes and providers, according to the release. A study sponsored by Embecta found the 300 U insulin reservoir would meet the 3-day insulin needs of 64% of people with type 2 diabetes, whereas a 200 U reservoir would meet the insulin needs of 38% of those with type 2 diabetes.

“FDA clearance of our disposable insulin delivery system has been a top strategic priority for our team since launching Embecta as an independent company, and achieving this milestone through strong execution exemplifies our commitment to making life better for the growing number of people living with diabetes,” Dev Kurdikar, CEO of Embecta, said in the release. “As we continue to advance toward our vision of a life unlimited by diabetes, our team has focused on developing a patch pump that could address some of the most significant obstacles to adopting pump therapy for people who use insulin daily to manage their diabetes. This platform is also serving as the basis for an automated insulin delivery system in development.”

In the release, Embecta said it plans to submit a closed-loop version of its system along with an insulin dosing algorithm to the FDA in the future.